<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03739112</url>
  </required_header>
  <id_info>
    <org_study_id>CP-PRO-QVLP-014</org_study_id>
    <nct_id>NCT03739112</nct_id>
  </id_info>
  <brief_title>Efficacy of a Plant-derived Quadrivalent VLP Vaccine in the Elderly</brief_title>
  <official_title>A Randomized, Observer-blind, Active Comparator-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-derived Quadrivalent VLP Influenza Vaccine in Adults 65 Years of Age and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicago</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3 study is intended to assess the relative efficacy of the Quadrivalent VLP&#xD;
      Influenza Vaccine during the 2018-2019 influenza season compared to a licensed vaccine in&#xD;
      elderly adults 65 years of age and older. One dose of Quadrivalent Virus-Like Particles (VLP)&#xD;
      Influenza Vaccine (30 μg/strain) or of Comparator (15 ug/strain) will be administered to&#xD;
      approximately 12,120 subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, observer-blind, active-controlled multicenter, Phase 3 study will be&#xD;
      conducted at multiple sites. The composition of the Quadrivalent VLP Influenza Vaccine to be&#xD;
      used in this study includes a mix of recombinant H1, H3, and two B hemagglutinin proteins&#xD;
      expressed as VLPs for the 2018-2019 influenza virus strains.&#xD;
&#xD;
      Approximately 12,120 healthy male and female subjects aged 65 years and older will be&#xD;
      randomized in a 1:1 ratio into one of two parallel treatment groups, such that approximately&#xD;
      6,060 subjects will receive the Quadrivalent VLP Influenza Vaccine at a dose of 30 μg/strain&#xD;
      and approximately 6,060 subjects will receive the comparator. Within the two treatment&#xD;
      groups, subjects will be stratified by site and two age groups (65-74 years of age and 75&#xD;
      years of age and older in a 2:1 ratio).&#xD;
&#xD;
      Subjects will participate in this study for approximately eight to ten months, during which a&#xD;
      first visit will be scheduled on Day 0 for screening and vaccine administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 18, 2018</start_date>
  <completion_date type="Actual">June 14, 2019</completion_date>
  <primary_completion_date type="Actual">May 17, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a randomized, observer-blind, active comparator-controlled, multicenter, Phase 3 efficacy study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Surveillance personnel is blinded from IP injection</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of protocol-defined Influenza-Like Illnesses (ILI) cause by any influenza viral type/subtype</measure>
    <time_frame>8 months</time_frame>
    <description>Occurrences of protocol-defined ILI due to laboratory-confirmed influenza viral type/sub-type (RT-PCR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of ILI cause by vaccine-matched strains</measure>
    <time_frame>8 months</time_frame>
    <description>Occurrences of laboratory-confirmed ILI caused by influenza viral types/subtypes that are matched (and/or antigenically similar) to the strains covered in the vaccination formulation (RT-PCR and serotyping)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of protocol-defined Respiratory Illnesses (RI) cause by vaccine-matched strains</measure>
    <time_frame>8 months</time_frame>
    <description>Occurrences of laboratory-confirmed RI caused by vaccine-matched strains sequential RT-PCR and serotyping)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of protocol-defined Respiratory Illnesses (RI) cause by any influenza viral types/subtypes</measure>
    <time_frame>8 months</time_frame>
    <description>Occurrences of laboratory-confirmed RI caused by any influenza viral types/subtypes (sequential RT-PCR and serotyping)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of ILI regardless of laboratory results</measure>
    <time_frame>8 months</time_frame>
    <description>Occurrences of ILI post vaccination confirmed or not by laboratory testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of solicited local and systemic reactions recorded in Diary</measure>
    <time_frame>15 minutes post-vaccination</time_frame>
    <description>Percentage, intensity, and relationship to vaccination of immediate complaints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of solicited local and systemic reactions recorded in Diary</measure>
    <time_frame>seven days following study vaccine administration</time_frame>
    <description>Percentage, intensity, and relationship to vaccination of solicited local and systemic signs and symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrences of unsolicited AEs up to 21 days post-vaccination</measure>
    <time_frame>21 days following study vaccine administration</time_frame>
    <description>Percentage, intensity, and relationship of TEAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Serious Adverse Events (SAE)</measure>
    <time_frame>8 months</time_frame>
    <description>Occurrences of death and SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events leading to withdrawal</measure>
    <time_frame>8 months</time_frame>
    <description>Occurrences of AEs leading to withdrawal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of New Onset of Chronic Disease (NOCD)</measure>
    <time_frame>8 months</time_frame>
    <description>Occurrences of NOCDs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI antibody response induced by QVLP against the homologous and heterologous influenza strains in a subset of 420 subjects</measure>
    <time_frame>21 days following study vaccine administration</time_frame>
    <description>GMT of HI antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI antibody response induced by QVLP against the homologous and heterologous influenza strains in a subset of 420 subjects</measure>
    <time_frame>21 days following study vaccine administration</time_frame>
    <description>SC rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI antibody response induced by QVLP against the homologous and heterologous influenza strains in a subset of 420 subjects</measure>
    <time_frame>21 days following study vaccine administration</time_frame>
    <description>SP rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HI antibody response induced by QVLP against the homologous and heterologous influenza strains in a subset of 420 subjects</measure>
    <time_frame>21 days following study vaccine administration</time_frame>
    <description>Geometric mean fold rise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MN antibody response induced by QVLP against the homologous influenza strains in a subset of 420 subjects</measure>
    <time_frame>21 days following study vaccine administration</time_frame>
    <description>GMT of MN antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MN antibody response induced by QVLP against the homologous influenza strains in a subset of 420 subjects</measure>
    <time_frame>21 days following study vaccine administration</time_frame>
    <description>SC rate of MN antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MN antibody response induced by QVLP against the homologous influenza strains in a subset of 420 subjects</measure>
    <time_frame>21 days following study vaccine administration</time_frame>
    <description>GMFR of MN antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SRH antibody response induced by QVLP against the homologous strains in a subset of 420 subjects</measure>
    <time_frame>21 days following study vaccine administration</time_frame>
    <description>Geometric mean area (GMA) of SRH antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SRH antibody response induced by QVLP against the homologous strains in a subset of 420 subjects</measure>
    <time_frame>21 days following study vaccine administration</time_frame>
    <description>SC rate of SRH antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SRH antibody response induced by QVLP against the homologous strains in a subset of 420 subjects</measure>
    <time_frame>21 days following study vaccine administration</time_frame>
    <description>SP rate of SRH antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SRH antibody response induced by QVLP against the homologous strains in a subset of 420 subjects</measure>
    <time_frame>21 days following study vaccine administration</time_frame>
    <description>GMFR of SRH antibody</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12793</enrollment>
  <condition>Virus Diseases</condition>
  <condition>RNA Virus Infections</condition>
  <condition>Respiratory Tract Diseases</condition>
  <condition>Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Quadrivalent VLP Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose - 30 µg/strain of Quadrivalent VLP Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quadrivalent Comparator Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose - 15 ug/strain of Quadrivalent Comparator Vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent VLP Vaccine</intervention_name>
    <description>Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine</description>
    <arm_group_label>Quadrivalent VLP Vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Comparator Vaccine</intervention_name>
    <description>Single dose of a 15 ug/strain of Quadrivalent Comparator Vaccine</description>
    <arm_group_label>Quadrivalent Comparator Vaccine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must have read, understood, and signed the informed consent form (ICF) prior&#xD;
             to participating in the study; subjects must also complete study-related procedures&#xD;
             and communicate with the study staff at visits and by phone during the study;&#xD;
&#xD;
          2. Subject must have a body mass index (BMI) ≤ 35 kg/m2;&#xD;
&#xD;
          3. Subjects are considered by the Investigator to be reliable and likely to cooperate&#xD;
             with the assessment procedures and be available for the duration of the study;&#xD;
&#xD;
          4. Male and female subjects must be 65 years of age and older at the&#xD;
             Screening/Vaccination visit (Visit 1);&#xD;
&#xD;
          5. Subjects must be non-institutionalized (e.g. not living in rehabilitation centres or&#xD;
             old-age homes; living in an elderly community is acceptable) and have no acute or&#xD;
             evolving medical problems prior to study participation and no clinically relevant&#xD;
             abnormalities that could jeopardize subject safety or interfere with study&#xD;
             assessments, as assessed by the Principal Investigator or sub-Investigator (thereafter&#xD;
             referred as Investigator) and determined by medical history, physical examination, and&#xD;
             vital signs;&#xD;
&#xD;
        Note: Subjects with a pre-existing chronic disease will be allowed to participate if the&#xD;
        disease is stable and, according to the Investigator's judgment, the condition is unlikely&#xD;
        to confound the results of the study or pose additional risk to the subject by&#xD;
        participating in the study. Stable disease is generally defined as no new onset or&#xD;
        exacerbation of pre-existing chronic disease three months prior to vaccination. Based on&#xD;
        the Investigator's judgment, a subject with more recent stabilization of a disease could&#xD;
        also be eligible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. According to the Investigator's opinion, history of an ongoing acute or evolving&#xD;
             medical or neuropsychiatric illness. 'Evolving' is defined as:&#xD;
&#xD;
               -  Requiring a new medical or surgical treatment during the three months prior to&#xD;
                  study vaccine administration unless the criteria outlined in inclusion criterion&#xD;
                  no. 5 can be met (i.e. the Investigator can justify inclusion based upon the&#xD;
                  innocuous nature of medical/surgical events and/or treatments);&#xD;
&#xD;
               -  Requiring any significant change in a chronic medication (i.e. drug, dose,&#xD;
                  frequency) during the three months prior to study vaccine administration due to&#xD;
                  uncontrolled symptoms or drug toxicity unless the innocuous nature of the&#xD;
                  medication change meets the criteria outlined in inclusion criterion no. 5 and is&#xD;
                  appropriately justified by the Investigator.&#xD;
&#xD;
          2. Any medical or neuropsychiatric condition or any history of excessive alcohol use or&#xD;
             drug abuse that would render the subject unable to provide informed consent or unable&#xD;
             to provide valid safety observations and reporting, including methadone (methadone as&#xD;
             treatment for opioid dependence may be acceptable if the subject has been otherwise&#xD;
             opioid-free for at least three years);&#xD;
&#xD;
          3. Any autoimmune disease other than hypothyroidism on stable replacement therapy&#xD;
             (including, but not limited to rheumatoid arthritis, systemic lupus erythematosus,&#xD;
             Crohn's disease, type 1 diabetes, and inflammatory bowel disease) or any confirmed or&#xD;
             suspected immunosuppressive condition or immunodeficiency including known or suspected&#xD;
             human immunodeficiency virus (HIV), Hepatitis B or C infection, the presence of&#xD;
             lymphoproliferative disease;&#xD;
&#xD;
          4. Any history of status asthmaticus or ongoing serious problems with asthma,&#xD;
             hospitalization for asthma control, or recurrent asthma episodes requiring medical&#xD;
             attention in the last three years (one or more episodes per year);&#xD;
&#xD;
          5. Administration or planned administration of any non-influenza vaccine within 30 days&#xD;
             prior to randomization up to blood sampling on Day 21. Immunization on an emergency&#xD;
             basis will be evaluated case-by-case by the Investigator;&#xD;
&#xD;
          6. Administration of any adjuvanted or investigational influenza vaccine within one year&#xD;
             prior to randomization or planned administration prior to the completion of the study;&#xD;
&#xD;
          7. Administration of any 'standard', non-adjuvanted influenza vaccine (e.g. live&#xD;
             attenuated trivalent/quadrivalent inactivated influenza vaccine or split&#xD;
             trivalent/quadrivalent inactivated influenza vaccine administered by intranasal,&#xD;
             intradermal, or intramuscular [IM] route) within six months prior to randomization and&#xD;
             up to completion of the study;&#xD;
&#xD;
          8. Use of any investigational or non-registered product within 30 days or five&#xD;
             half-lives, whichever is longer, prior to randomization or planned use during the&#xD;
             study period. Subjects may not participate in any other investigational or marketed&#xD;
             drug study while participating in this study until after the study;&#xD;
&#xD;
          9. Treatment with systemic glucocorticoids at a dose exceeding 10 mg of prednisone (or&#xD;
             equivalent) per day for more than seven consecutive days or for ten or more days in&#xD;
             total, within one month of study vaccine administration; any other cytotoxic or&#xD;
             immunosuppressant drug, or any immunoglobulin preparation within three months of&#xD;
             vaccination and until the completion of the study. Low doses of nasal or inhaled&#xD;
             glucocorticoids are allowed. Topical steroids are permitted;&#xD;
&#xD;
         10. Any significant disorder of coagulation including, but not limited to, treatment with&#xD;
             warfarin derivatives or heparin. Persons receiving prophylactic anti-platelet&#xD;
             medications (e.g. low-dose aspirin [no more than 100 mg/day]), and without a&#xD;
             clinically apparent bleeding tendency are eligible. Subjects treated with new&#xD;
             generation drugs that do not increase the risk of IM bleeding (e.g. clopidogrel) are&#xD;
             also eligible;&#xD;
&#xD;
         11. History of allergy to any of the constituents of the Quadrivalent VLP Influenza&#xD;
             Vaccine, any components of the active comparator quadrivalent vaccine, or tobacco;&#xD;
&#xD;
         12. History of anaphylactic allergic reactions to plants or plants components (including&#xD;
             fruits and nuts);&#xD;
&#xD;
         13. Use of antihistamines within 48 hours prior to study vaccination;&#xD;
&#xD;
         14. Daily use of large doses of medication for pain control or inflammation (e.g. opioids,&#xD;
             nonsteroidal anti-inflammatory drugs [NSAIDs]). Use of a singular regular dose either&#xD;
             in the morning or at bedtime would not be exclusionary;&#xD;
&#xD;
         15. Use of prophylactic medications (e.g. acetaminophen/paracetamol, aspirin, naproxen, or&#xD;
             ibuprofen) within 24 hours of randomization to prevent or pre-empt symptoms due to&#xD;
             vaccination;&#xD;
&#xD;
         16. Planned use of influenza antiviral treatment medication before the collection of NP&#xD;
             swabs (e.g. oseltamivir, zanamivir, rapivab);&#xD;
&#xD;
         17. Have a rash, dermatological condition, tattoos, muscle mass, or any other&#xD;
             abnormalities at the injection site that may interfere with injection site reaction&#xD;
             rating;&#xD;
&#xD;
         18. Subjects who have received a blood transfusion within 90 days prior to study&#xD;
             vaccination;&#xD;
&#xD;
         19. Subjects with abnormal vital signs (systolic blood pressure [BP] ≥ 150 mmHg and/or&#xD;
             diastolic BP ≥ 95 mmHg for individuals taking antihypertensive medication and ≥ 140&#xD;
             mmHg and/or diastolic BP ≥ 90 mmHg for individuals not taking antihypertensive&#xD;
             medication; heart rate [HR] ≤ 45 beats/min and ≥ 100 beats/min) evaluated by an&#xD;
             Investigator to be clinically significant. A subject with abnormal vital signs results&#xD;
             may be included in the study based on Investigator's judgment (e.g. a resting HR ≤ 45&#xD;
             in highly trained athletes);&#xD;
&#xD;
         20. Presence of any febrile illness (including an oral temperature [OT] ≥ 38.0 ˚C within&#xD;
             24 hours prior to vaccination;&#xD;
&#xD;
         21. Cancer or treatment for cancer within three years prior to study vaccine&#xD;
             administration. Persons with a history of cancer who are disease-free without&#xD;
             treatment for three years or more are eligible. However, individuals with conditions&#xD;
             such as treated and uncomplicated basal cell carcinoma of the skin or non-treated,&#xD;
             non-disseminated local prostate cancer may be eligible;&#xD;
&#xD;
         22. Subjects identified as an Investigator or employee of the Investigator or clinical&#xD;
             site with direct involvement in the proposed study, or identified as an immediate&#xD;
             family member (i.e. parent, spouse) of the Investigator or any employee of Medicago&#xD;
             (or their family members);&#xD;
&#xD;
         23. Subjects with a history of Guillain-Barré Syndrome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sébastien Soucy</last_name>
    <role>Study Chair</role>
    <affiliation>Director, Clinical Studies</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian Ward</last_name>
    <role>Study Director</role>
    <affiliation>Medical Officer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>(Site 225) Coastal Clinical Research</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 201) Clinical Research Consortium</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 213) Advanced Clinical Research</name>
      <address>
        <city>Banning</city>
        <state>California</state>
        <zip>92220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 246) Paradigm Clinical Research / Pharmaseek</name>
      <address>
        <city>Redding</city>
        <state>California</state>
        <zip>96001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 212) Benckmark Research</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95864</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 244) Paradigm Clinical Research Center Inc</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 242) Paradigm Clinical Research Centers Inc</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 239) Alliance for Multispeciality Research</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 222) Research Centers of America</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 221) St-Johns Center for Clinical Research</name>
      <address>
        <city>Ponte Vedra</city>
        <state>Florida</state>
        <zip>32081</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 231) QPS-MRA LLC</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 251) Meridian Clinical Research</name>
      <address>
        <city>Richmond Hill</city>
        <state>Georgia</state>
        <zip>31324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 240) Meridian Clinical Research LLC</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 223) Clinical Research Atlanta</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 249) Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 219) Heartland Research Associates LLC</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 234) Heartland Research Associates LLC</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 215) Heartland Research Associates LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 235) Heartland Research Associates LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 241) Central Kentucky Reserach Associates</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 203) Benchmark Research</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 227) Sundande Clinical Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 226) Meridian Clinical Research LLC</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 211) Meridian Clinical Research</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 209) United Medical Associates</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 217) Regional Clinical Research inc</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 237) PMG Research of Cary LLC</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 230) PMG Research of Charlotte LLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 205) PMG Research of Rocky Mount LLC</name>
      <address>
        <city>Rocky Mount</city>
        <state>North Carolina</state>
        <zip>27804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 236) PMG Research</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 228) Research of Winston-Salem</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 233) Sterling Research Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 208) Sterling Research Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 245) Rapid Medical Research</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 202) Aventiv Research Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 207) Lynn Institute of Norman</name>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <zip>73069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 238) Tekton Research</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 216) PMG Research of Charleston LLC</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 248) Coastal Carolina Research Center</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 201) Meridian Clinical Research</name>
      <address>
        <city>Dakota Dunes</city>
        <state>South Dakota</state>
        <zip>57049</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 247) New orleans Center for Clinical Research</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 206) Benchmark Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 218) Tekton Research Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 214) Ventavia Research Group LLC</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 224) Benchmark Research</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 232) Benchmark Research</name>
      <address>
        <city>San Angelo</city>
        <state>Texas</state>
        <zip>76904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 250) Clinical Trials of Texas Inc</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 204) Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 220) Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 229) Clinical Research Associates of Tidewater</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 106) Colchester Research Group</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 113) Dawson Road Family Medical Clinic</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <zip>N1H 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 110) Manna Research Inc.</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 103) Q &amp; T Recherche Chicoutimi</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 7Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 105) Q &amp; T Outaouais</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y 6S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 107) Manna Research Inc.</name>
      <address>
        <city>Levis</city>
        <state>Quebec</state>
        <zip>G6W 0M6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 109) Manna Research Inc. (Mirabel)</name>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 108) Manna Research</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 102) CHU de Québec - Université Laval</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G1E 7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(site 101) Centre de Recherche St-Louis</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 110) Alpha Recherche Clinique</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G3K 2P8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 104) Q &amp; T Recherche Sherbrooke</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1J 2G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 112) Medexa Recherche</name>
      <address>
        <city>Victoriaville</city>
        <state>Quebec</state>
        <zip>G6P 6P6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 309) Espoo Vaccine Research Clinic</name>
      <address>
        <city>Espoo</city>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 303) Helsinki South Vaccine Research Clinic</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 308) Helsinki East Vaccine Research Center</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 301) Jarvenpaa Vaccine Research Clinic</name>
      <address>
        <city>Järvenpää</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 306) Kokkola Vaccine Research Clinic</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 304) Oulu Vaccine Research Clinic</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 302) Tampere University Vaccine Research Center</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 305) Seinaejoki Vaccine Research Clinic</name>
      <address>
        <city>Seinäjoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 310) Tampere Vaccine Research Clinic</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 307) Turku Vaccine Research Center</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 410) Emovis GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 418) Klinische Forschung Berlin GbR</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 422) Synexus Clinical Research GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 402) Synexus Clinical research GmbH</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 409) Gemeinschaftspraxis Dr. med Kleinecke-Pohl</name>
      <address>
        <city>Cologne</city>
        <zip>51069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 401) Cardiologicum Dresden &amp; Pirna</name>
      <address>
        <city>Dresden</city>
        <zip>01277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 406) Diabetologische Germeinschafts praxis Faulman</name>
      <address>
        <city>Dresden</city>
        <zip>1279</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 405) Doktor Markus Faghih</name>
      <address>
        <city>Essen</city>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 407) Klinisches Forschungszentrum Dr. Hagemann am Hausarztzer</name>
      <address>
        <city>Essen</city>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 417) Medizentrum Essen-Borbeck</name>
      <address>
        <city>Essen</city>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 414) Unterfrintroper Hausarztzentrum Klinische Forschung</name>
      <address>
        <city>Essen</city>
        <zip>45359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(SIte 404) Synexus Clinical Reserach GmbH</name>
      <address>
        <city>Frankfurt</city>
        <zip>60313</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 411) MedicoKIT GmbH</name>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 425) Clinical Research Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 403) Praxis Dr. Med Cornelia Brauer</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 408) Germeinsschaftspraxis Dr. med Christiane Klein/Minnich</name>
      <address>
        <city>Künzing</city>
        <zip>94550</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 421) SIBAmed Studienzentrum GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>01403</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 420) Synexus Clinical Research GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 423) centrum fuer Diagnostik und Gesundheit</name>
      <address>
        <city>Munich</city>
        <zip>80809</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 413) Dr. Ingomar F.K. Naudts MD Office</name>
      <address>
        <city>Rodgau</city>
        <zip>63110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 415) Praxisgemeinschaft Stuhr-Brinkum</name>
      <address>
        <city>Stuhr</city>
        <zip>28816</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 416) Praxis Dr. med Joachim Sauter</name>
      <address>
        <city>Wangen</city>
        <zip>88239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 412) MALU-Medizinische Studien GmbH</name>
      <address>
        <city>Wardenburg</city>
        <zip>26203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 424) Medislim GmbH</name>
      <address>
        <city>Weinheim</city>
        <zip>69469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 603) Ramathibodi Hospital, Mahid - Division of Infectious Disease</name>
      <address>
        <city>Bangkok</city>
        <zip>10160</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 606) Faculty of Tropical Medicine, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 608) Phramongkutklao Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 609) Division of Tropical Pediatrics</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 601) Faculty of Medicine, Chiang Mai University</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 607) Srinagarind Hospital Khon Kaen University</name>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(Site 605) Golden Jubilee Medical Center</name>
      <address>
        <city>Nakhon Pathom</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ward BJ, Makarkov A, Séguin A, Pillet S, Trépanier S, Dhaliwall J, Libman MD, Vesikari T, Landry N. Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials. Lancet. 2020 Nov 7;396(10261):1491-1503. doi: 10.1016/S0140-6736(20)32014-6. Epub 2020 Oct 13.</citation>
    <PMID>33065035</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2018</study_first_posted>
  <last_update_submitted>October 29, 2020</last_update_submitted>
  <last_update_submitted_qc>October 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>RNA Virus Infections</mesh_term>
    <mesh_term>Respiratory Tract Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

